Patent monopolies are tolerated because we believe they promote progress that benefits society. What should be done when these monopolies actually increase human suffering? Drug prices in America are fifty to eighty percent higher than the rest of the world, meaning many cannot afford drugs that will improve or even save their lives. When striking a balance between the interests of the patent holder and that of the public, it is important to bear in mind that the rewards granted to patentees are secondary to the public benefit derived from their labors. The ideal solution would come from Congress creating a need-based exception to drug patent infringement, but this is unlikely to occur. An infrequently used statutory exemption, found in Sec...
Each year, billions of people lack adequate access to urgently required medicines, leading to unnece...
Although there has been substantial discussion of the proper scope of patentable subject matter in r...
The article is divided into six parts. Part one deals with the introduction, part two discusses the ...
The pharmaceutical business is dominated largely by two types of entities: large, research-intensive...
The U.S. Supreme Court effectively redefined the scope of patent eligible subject matter when it dec...
The push to lower pharmaceutical drug prices has taken a stronger foothold in legislative and execut...
High drug prices are creating serious health and fiscal problems in the United States to...
This article argues that universal access to drugs requires not only collaboration between nations a...
There is debate among scholars as to whether patent law provides more benefit than harm. Some studie...
Outrageous drug prices have dominated news coverage of the American healthcare system for years. Yet...
This paper offers an economic rationale for compulsory licensing of needed medicines in developing c...
The role of the patent system in promoting pharmaceutical innovation is widely seen as a tremendous ...
Monopolies over many life-saving drugs have led to high prices that remain out of reach for patients...
Brand-name pharmaceutical companies create pioneer drugs that cure diseases around the world. Howeve...
There is a shift in the shape of intellectual property tools used to strengthen and lengthen the rig...
Each year, billions of people lack adequate access to urgently required medicines, leading to unnece...
Although there has been substantial discussion of the proper scope of patentable subject matter in r...
The article is divided into six parts. Part one deals with the introduction, part two discusses the ...
The pharmaceutical business is dominated largely by two types of entities: large, research-intensive...
The U.S. Supreme Court effectively redefined the scope of patent eligible subject matter when it dec...
The push to lower pharmaceutical drug prices has taken a stronger foothold in legislative and execut...
High drug prices are creating serious health and fiscal problems in the United States to...
This article argues that universal access to drugs requires not only collaboration between nations a...
There is debate among scholars as to whether patent law provides more benefit than harm. Some studie...
Outrageous drug prices have dominated news coverage of the American healthcare system for years. Yet...
This paper offers an economic rationale for compulsory licensing of needed medicines in developing c...
The role of the patent system in promoting pharmaceutical innovation is widely seen as a tremendous ...
Monopolies over many life-saving drugs have led to high prices that remain out of reach for patients...
Brand-name pharmaceutical companies create pioneer drugs that cure diseases around the world. Howeve...
There is a shift in the shape of intellectual property tools used to strengthen and lengthen the rig...
Each year, billions of people lack adequate access to urgently required medicines, leading to unnece...
Although there has been substantial discussion of the proper scope of patentable subject matter in r...
The article is divided into six parts. Part one deals with the introduction, part two discusses the ...